GVAX Vaccine for Pancreatic Cancers

GVAX is a vaccine made from pancreatic cancer cells that have been genetically modified to produce the cytokine GM-CSF, which stimulates the immune system. The cells are then irradiated to prevent cell growth. Results from a phase II clinical… [Learn More…]

MRI for Pre-surgical Detection of Mutations in Brain Tumors

Mutations in the isocitrate dehydrogenase genes (IDH1 and IDH2) are found in roughly 70 % of low and intermediate-grade gliomas, and the presence of these mutations means patients generally survive longer, but don’t respond as well to standard… [Learn More…]

Validation of Vemurafenib in Previously Treated BRAF V600 – Mutated Metastatic Melanoma: BRIM 2 Update

Vemurafenib (PLX4032) is a next generation oral BRAF inhibitor for the treatment of metastatic melanoma harbouring the BRAF V600 mutation. Update from the BRIM 2 trial on previously treated patients has shown that 53% of the patients experienced… [Learn More…]

RANK-ing the Effects of Denosumab in Prostate Cancer Patients with High PSA doubling Times

Metastasis to the bone is a common feature of prostate cancers. When prostate cancers metastasize to the bone, they hijack the bone remodelling process in order to be incorporated into the newly developed bone tissue. Denosumab is a monoclonal… [Learn More…]

Diagnosis and Classification of Brain Tumors Using Mass Spectrometry

Brain tissue biopsies obtained during surgery are used to histologically diagnose and grade brain tumors, to discriminate normal from diseased tissue and to determine the best treatments. However, this approach is limited by tissue characterization… [Learn More…]

Adjunct TG4010 for Advanced Non-Small Cell Lung Cancer (NSCLC)

TG4010 (MVA-MUC1-IL2) is a poxvirus vector that has been adapted to target MUC1, which is a major tumor-associated antigen. MVA is a highly attenuated (non-pathogenic) strain, which has been tested extensively in humans as a smallpox vaccine and is… [Learn More…]

Pertuzumab Update: The New Kid on “HER” Block

  Although trastuzumab has led to significant improvements in treating HER2-positive breast cancers, many patients relapse and develop resistance to trastuzumab. The HER family of growth factor receptors consists of four closely related… [Learn More…]

Zoledronic Acid Update

Adjuvant therapy with non-nitrogenous bisphosphonates has not been shown to improve progression free survival (PFS) and overall survival (OS) in estrogen positive breast cancer patients. A clinical trial meta analysis of adjuvant clodronate… [Learn More…]

Pertuzumab: The New Kid on “HER” Block

Approximately 20% of all breast cancers are caused by the oncogenic human epidermal growth factor receptor 2 (HER2) and although trastuzumab has led to significant improvements in treating HER2-positive breast cancers, many patients develop… [Learn More…]

S-1: A Synergistic Drug Combination that Improves Overall Survival in Patients with Stage II and III Gastric Cancer

S-1 (TS-1) is a chemotherapeutic preparation combining tegafur, gimeracil and oteracil potassium in a molar ratio of 1:0.4:1 that significantly improves overall survival in patients with stage II or III gastric cancer. In this study, patients that… [Learn More…]